

## **Supplementary Figures**

## Supplementary figure 1




С




Supplementary figure 1. (a) Twelve µm-thick slices from human colonic biopsies were incubated with antibodies against FXR (in green) and GLP-1 (in red). Nuclei are in blue. This experiment is representative of 3 different FXR/GLP-1 immunostainings. Scale bar represents 100 µm. Magnification 63X. (b) *Fgf15* qPCR on cDNA from ileum and colon of 8-week old WT mice treated by gavage for 5 days with GW4064 (30 mg/kg, n=5 mice/group). (c) *FGF19* qPCR on cDNA of human jejunal biopsies from 4 normoglycemic patients *ex vivo* treated for 16h with GW4064 (5 µmol L<sup>-1</sup>) (n=3/group). Data are represented as mean +/- SD. Student t test, \**P*≤0.05 & \*\*\**P*≤0.001.

## Supplementary figure 2




**Supplementary figure 2.** (a) Proglucagon qPCR on cDNA from GLUTag cells treated for 24h with GW4064 (10  $\mu$ mol L<sup>-1</sup>) or CDCA (100  $\mu$ mol L<sup>-1</sup>) (n=3; representative of 4 different experiments). Data are represented as mean +/- SD. One-Way ANOVA followed by Tukey's post-hoc test. \*\*\*\**P*≤0.001 vs DMSO. (b) Proglucagon pre-mRNA quantification on cDNA from GLUTag cells treated for 24h with GW4064 (5  $\mu$ mol L<sup>-1</sup>) (n=3; representative of 4 different experiments). Data are represented as mean +/- SD. Student t test, \*\*\**P*≤0.001.




Supplementary figure 3. *Chrebp* qPCR on cDNA from GLUTag cells electroporated with a siCtrl or si*Chrebp*, starved for 12h with lactate (10 mmol L<sup>-1</sup>) and then incubated for 24h in lactate 10 mmol L<sup>-1</sup> (Glc -) or glucose 5.6 mmol L<sup>-1</sup> (Glc +) media supplemented with DMSO or GW4064 (5 µmol L<sup>-1</sup>) (n=3; representative of 4 different experiments). Data are represented as mean +/- SD. Two-Way ANOVA analysis followed by Bonferronni's posthoc test. <sup>§§§</sup>*P*≤0.001: effect of si*Chrebp* in each treatment condition.

Supplementary figure 4



**Supplementary figure 4.** Oxygen consumption rate (OCR) after successive injection of glucose (10 mmol L<sup>-1</sup>), oligomycin (1µmol L<sup>-1</sup>), 2-deoxyglucose (100 mmol L<sup>-1</sup>) and rotenone (1µmol L<sup>-1</sup>) / antimycin A (1 µmol L<sup>-1</sup>) on GLUTag cells incubated 24h with DMSO or GW4064 (5 µmol L<sup>-1</sup>) (n=3; representative of 4 different experiments). Data are represented as mean +/- SD. Two-Way ANOVA analysis followed by Bonferronni's posthoc test. \*\*\**P*≤0.001: effect of GW4064 on OCR from t=0min to t=15min.

Supplementary figure 5



**Supplementary figure 5.** *Fgf15* qPCR on cDNA from ileum (**a**) or from colon (**b**) of 8 week-old *Fxr+/+*, *Fxr-/-* male mice on an *ob/ob* background fed for 2 weeks with a diet enriched or not with 2% colesevelam (n=6-7 mice/group). Data are represented as mean +/- SEM. (**c**) Proglucagon qPCR on cDNA from colon of 8 week-old *Fxr+/+*, *Fxr-/-* male mice on an *ob/ob* background fed for 2 weeks with a diet enriched or not with 2% colesevelam (n=6-7 mice/group). Data are represented as mean +/- SEM. Two-Way ANOVA analysis followed by Bonferronni's posthoc test. \**P*≤0.05, \*\**P*≤0.01 and \*\*\**P*≤0.001: effect of Colesevelam treatment on gene expression in each genotype. <sup>§</sup>*P*≤0.05 and <sup>§§§</sup>*P*≤0.001: effect of FXR-deficiency on gene expression in each treatment condition.